Status:
COMPLETED
Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Chiesi Farmaceutici S.p.A.
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-100 years
Brief Summary
This study is assessing the impact of timing of PD assessments on measures of platelet reactivity in patients undergoing PCI treated with cangrelor.
Detailed Description
Cangrelor is characterized by reversible binding to the P2Y12 receptor and is promptly inactivated through dephosphorylation by ectonucleotidase leading to its very short plasma half-life. Consequentl...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI and treated with cangrelor per standard of care.
- Treated with aspirin prior to the PCI procedure per standard of care
Exclusion
- Treatment with an oral P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) within past 10 days
- Treatment with oral anticoagulation (vitamin K antagonist, dabigatran, apixaban, rivaroxiban) within past 3 days
- Treatment with a glycoprotein IIb/IIIa inhibitor during PCI
- Fibrinolytics within 48 hours
- Known hemoglobin\<10 gm/dL
- Known platelet count \<80x106/mL
- Active bleeding or hemodynamic instability
- Known end stage renal disease on hemodialysis
- Known severe hepatic dysfunction
Key Trial Info
Start Date :
January 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 20 2021
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04668495
Start Date
January 28 2021
End Date
July 20 2021
Last Update
September 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Jacksonville, Florida, United States, 32209